United States, December 15, 2025, the FDA has officially removed a massive roadblock for medical device manufacturers. The agency announced a “common-sense reform” that changes how companies can use Real-World Evidence (RWE) to get products approved. For years, manufacturers wanted to use large, real-world databases to prove their devices worked. But the FDA had a strict rule: if you submit RWE, you generally had to provide identifiable individual patient data. This was a problem because most massive, valuable datasets (like hospital records or insurance claims) are de-identified for privacy. Because manufacturers couldn’t provide the private patient names or IDs, the FDA often rejected the data.
That rule is now gone for medical device submissions.
WHAT THIS MEANS FOR MEDICAL DEVICE MANUFACTURERS
If you are a device manufacturer, this is a green light to change your data strategy. Here is the direct impact:
You Can Now Use “Big Data”: You are no longer restricted to data where you can identify the specific patient. You can now utilize massive, de-identified databases that were previously “off-limits” or impractical to use.
Access to New Goldmines of Information: The FDA specifically mentioned they are opening the door to:
- National cancer registries (like NCI’s SEER).
- Hospital system databases.
- Insurance claims databases.
- Electronic Health Record (EHR) networks.
Faster Approvals (Potentially): By removing this barrier, the FDA aims to get “life-changing treatments to patients faster”. Instead of running expensive, slow clinical trials for every single metric, you can potentially back up your application with data that already exists in these registries.
Case-by-Case Review: It is not a free-for-all. FDA reviewers will still look at the “strength” of your evidence on an application-by-application basis, but the automatic “no” because of missing patient IDs is gone.
REAL-WORLD EVIDENCE: THE 'BEFORE AND AFTER' CONTEXT
To understand why this matters, look at the trend lines:
- The Plateau: Since 2016, over 250 device authorizations have used RWE, which was good. However, the rate had “plateaued” recently because the easy data was used up, and the strict privacy rules blocked the bigger datasets.
- The Reform: FDA Commissioner Dr. Marty Makary stated that the old barriers were “unnecessary” and that meaningful insights can be extracted from big data without needing to know exactly who the patient is.
FINAL SUMMARY
For device makers, the regulatory playground just got bigger. You can now leverage millions of patient records to prove your device works in the real world, without the bureaucratic nightmare of trying to de-anonymize private data.